These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 26008812)

  • 1. LRRK2 Pathways Leading to Neurodegeneration.
    Cookson MR
    Curr Neurol Neurosci Rep; 2015 Jul; 15(7):42. PubMed ID: 26008812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
    Xiong Y; Dawson VL; Dawson TM
    Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
    Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
    Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
    Gandhi PN; Chen SG; Wilson-Delfosse AL
    J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of LRRK2-mediated neurodegeneration.
    Tsika E; Moore DJ
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):251-60. PubMed ID: 22441981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.
    Yang D; Thomas JM; Li T; Lee Y; Liu Z; Smith WW
    Biochem Cell Biol; 2018 Aug; 96(4):441-449. PubMed ID: 29268033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.
    Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA
    Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.
    Verma M; Steer EK; Chu CT
    Biochim Biophys Acta; 2014 Aug; 1842(8):1273-81. PubMed ID: 24225420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
    Daniëls V; Baekelandt V; Taymans JM
    Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
    Greggio E; Cookson MR
    ASN Neuro; 2009 Apr; 1(1):. PubMed ID: 19570025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 and mitochondria: Recent advances and current views.
    Singh A; Zhi L; Zhang H
    Brain Res; 2019 Jan; 1702():96-104. PubMed ID: 29894679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.
    Bravo-San Pedro JM; Gómez-Sánchez R; Niso-Santano M; Pizarro-Estrella E; González-Polo RA; Fuentes JM
    Biochem Soc Trans; 2012 Oct; 40(5):1129-33. PubMed ID: 22988877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
    Lu YW; Tan EK
    J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
    Drolet RE; Sanders JM; Kern JT
    J Neurogenet; 2011 Dec; 25(4):140-51. PubMed ID: 22077787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.